Owens & Minor's Q3 Net Loss Widens to $150M Amid P&HS Divestiture

Ticker: ACH · Form: 10-Q · Filed: Oct 31, 2025 · CIK: 75252

Sentiment: bearish

Topics: Healthcare Distribution, Divestiture, Net Loss, Discontinued Operations, Strategic Restructuring, Q3 Earnings, Balance Sheet Impact

Related Tickers: OMI

TL;DR

**Owens & Minor is taking a huge one-time hit to shed its P&HS segment, but the cash infusion and streamlined focus could make it a leaner, more investable company post-divestiture.**

AI Summary

Owens & Minor Inc. reported a significant net loss of $150.276 million for the three months ended September 30, 2025, a substantial increase from the $12.770 million net loss in the prior year period. For the nine months ended September 30, 2025, the net loss ballooned to $1.044 billion, compared to $66.570 million in 2024. This dramatic increase is primarily driven by a massive loss from discontinued operations, net of tax, totaling $951.077 million for the nine-month period, largely due to a $771.640 million loss on classification to held for sale related to its Products & Healthcare Services (P&HS) segment. Net revenue saw a modest increase, reaching $697.264 million for the quarter and $2.053 billion for the nine months, up from $686.846 million and $1.985 billion respectively. Operating income, however, declined to $26.470 million for the quarter from $31.079 million, and sharply to $6.551 million for the nine months from $54.969 million, impacted by an $80 million transaction breakage fee and increased acquisition-related charges. The company is actively selling its P&HS segment for $375 million in cash, expected to close in Q1 2026, retaining a 5% equity interest.

Why It Matters

This filing reveals a company in significant transition, with a massive net loss primarily due to the divestiture of its P&HS segment. For investors, the $771.640 million loss on classification to held for sale is a critical one-time hit, but the $375 million cash sale could provide much-needed liquidity and focus for the remaining operations. Employees in the P&HS segment face uncertainty as the business changes hands, while customers may see shifts in service or product offerings post-acquisition. The broader market will watch how Owens & Minor navigates this strategic pivot, especially given the competitive landscape in healthcare distribution and services, where efficiency and scale are paramount. The company's ability to stabilize its continuing operations after shedding a major segment will be key to its future viability.

Risk Assessment

Risk Level: high — The company reported a net loss of $1.044 billion for the nine months ended September 30, 2025, primarily due to a $951.077 million loss from discontinued operations, including a $771.640 million loss on classification to held for sale. This substantial loss, coupled with a negative total equity of $(429.507) million as of September 30, 2025, compared to positive equity of $586.364 million at December 31, 2024, indicates significant financial distress and uncertainty during this transitional period.

Analyst Insight

Investors should closely monitor the successful completion of the P&HS segment sale and the subsequent use of the $375 million cash proceeds. Evaluate the performance of the continuing operations post-divestiture, focusing on operating income and cash flow generation, as the company aims to stabilize its financial position after this significant restructuring.

Financial Highlights

debt To Equity
N/A
revenue
$2,053,065,000
operating Margin
0.3%
total Assets
N/A
total Debt
N/A
net Income
-$1,044,316,000
eps
-$13.55
gross Margin
N/A
cash Position
N/A
revenue Growth
+3.4%

Revenue Breakdown

SegmentRevenueGrowth
Total Net Revenue$2,053,065,000+3.4%

Key Numbers

Key Players & Entities

FAQ

Why did Owens & Minor's net loss increase so dramatically in Q3 2025?

Owens & Minor's net loss increased dramatically primarily due to a $951.077 million loss from discontinued operations for the nine months ended September 30, 2025. This includes a significant $771.640 million loss on classification to held for sale related to the anticipated sale of its Products & Healthcare Services (P&HS) segment.

What is the status of the Owens & Minor P&HS segment sale?

Owens & Minor entered into an Equity Purchase Agreement on October 7, 2025, to sell its P&HS segment to Dominion Healthcare Acquisition Corporation for $375 million in cash. The sale is subject to customary closing conditions, including regulatory approvals, and is expected to close in the first quarter of 2026.

How much cash will Owens & Minor receive from the P&HS segment sale?

Owens & Minor is expected to receive an aggregate of $375 million in cash from the sale of its P&HS segment. This amount is subject to certain adjustments for cash, indebtedness, net working capital, and transaction expenses.

What was Owens & Minor's net revenue for the three months ended September 30, 2025?

For the three months ended September 30, 2025, Owens & Minor reported net revenue of $697.264 million. This represents a slight increase compared to $686.846 million for the same period in 2024.

What is Owens & Minor's current equity position?

As of September 30, 2025, Owens & Minor reported a total (deficit) equity of $(429.507) million. This is a significant decrease from the positive total equity of $586.364 million reported as of December 31, 2024.

What are the primary risks associated with Owens & Minor's current financial situation?

The primary risks include the substantial net loss of $1.044 billion for the nine months, the negative total equity of $(429.507) million, and the successful completion and integration of the P&HS segment divestiture. There's also the risk of potential termination fees of $9.4 million or $19 million if the P&HS sale does not close under certain circumstances.

How did the P&HS segment classification impact Owens & Minor's balance sheet?

The classification of the P&HS segment as held for sale significantly impacted the balance sheet. Current assets held for sale - discontinued operations increased to $1.764 billion at September 30, 2025, from $1.625 billion at December 31, 2024, while noncurrent assets held for sale decreased to zero from $731.193 million. Current liabilities held for sale also increased to $1.345 billion.

What is Owens & Minor's strategic outlook after the P&HS divestiture?

Following the P&HS divestiture, Owens & Minor's continuing operations will comprise a single operating and reporting segment. The strategic outlook involves focusing on this streamlined business, leveraging the $375 million cash proceeds, and aiming to stabilize financial performance after the significant one-time charges associated with the sale.

What was the impact of the accounting error correction on Owens & Minor's retained earnings?

An accounting error related to the over accrual of accounts payable was corrected, resulting in a cumulative increase of $21 million to Owens & Minor's retained earnings as of the earliest balance sheet date presented. This error was deemed immaterial to prior period financial statements.

What should investors consider regarding Owens & Minor's common stock?

Investors should note the basic net loss per common share of $(13.55) for the nine months ended September 30, 2025, a significant decline from $(0.87) in 2024. The company also repurchased $6.656 million of common stock during the nine-month period, which could indicate management's view on undervaluation despite the losses.

Risk Factors

Industry Context

Owens & Minor operates in the highly competitive healthcare distribution and medical products manufacturing sectors. The industry is characterized by consolidation, increasing demand for efficiency, and evolving regulatory landscapes. Companies like Owens & Minor face pressure to manage complex supply chains, integrate acquisitions, and adapt to shifts in healthcare delivery models.

Regulatory Implications

The divestiture of the P&HS segment may be subject to regulatory review and approval in various jurisdictions, potentially impacting the timing and completion of the sale. Changes in healthcare policy or reimbursement rates could also affect the company's core businesses.

What Investors Should Do

  1. Monitor the closing of the P&HS segment sale.
  2. Analyze the performance of the remaining 'Products & Healthcare Services' segment post-divestiture.
  3. Assess the company's ability to manage its debt and operating costs.
  4. Evaluate the strategic rationale and execution of the divestiture.

Key Dates

Glossary

Discontinued Operations
A component of a business that has been disposed of or is classified as held for sale, and whose operations and cash flows can be separately identified. (The significant loss from discontinued operations, primarily related to the P&HS segment, is the main driver of the company's large net loss for the period.)
Held for Sale
Assets that management has committed to sell and are available for immediate sale in their present condition, and the sale is probable within one year. (The P&HS segment was classified as held for sale, leading to a large non-cash loss recognized on its valuation.)
Transaction Breakage Fee
A fee incurred when a previously agreed-upon transaction is terminated or broken. (An $80 million fee was incurred, negatively impacting operating income for the nine-month period.)
Equity (Deficit)
The net worth of a company, calculated as total assets minus total liabilities. A deficit means liabilities exceed assets. (The company has a significant negative equity position of $(429.507) million as of September 30, 2025, indicating financial distress.)
Operating Income
A company's gross profit minus its operating expenses, excluding interest and taxes. (Operating income has sharply declined, highlighting operational challenges and the impact of one-time charges.)

Year-Over-Year Comparison

Owens & Minor has experienced a dramatic deterioration in its financial performance compared to the prior year. Net revenue saw a modest increase of 3.4% for the nine months, but net income has swung from a loss of $66.570 million to a staggering $1.044 billion loss. Operating income has also fallen sharply from $54.969 million to $6.551 million, impacted by significant one-time charges. The company's equity position has shifted from positive to a substantial deficit, underscoring the severe financial headwinds faced.

Filing Stats: 4,481 words · 18 min read · ~15 pages · Grade level 14.2 · Accepted 2025-10-30 17:35:35

Key Financial Figures

Filing Documents

Financial Information

Part I. Financial Information Page Item 1.

Financial Statements

Financial Statements 3 Condensed Consolidated Statements of Operations—Three and Nine Months Ended September 30, 2025 and 2024 3 Condensed Consolidated Statements of Comprehensive (Loss) Income—Three and Nine Months Ended September 30, 2025 and 2024 4 Condensed Consolidated Balance Sheets—September 30, 2025 and December 31, 2024 5 Condensed Consolidated Statements of Cash Flows—Nine Months Ended September 30, 2025 and 2024 6 Condensed Consolidated Statements of Changes in Equity (Deficit)—Three and Nine Months Ended September 30, 2025 and 2024 7 Notes to Condensed Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 31 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 42 Item 4.

Controls and Procedures

Controls and Procedures 42

Other Information

Part II. Other Information Item 1.

Legal Proceedings

Legal Proceedings 42 Item 1A.

Risk Factors

Risk Factors 42 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 45 Item 5. Other Information 45 Item 6. Exhibits 46

Signatures

Signatures 47 2 Table of Contents

Financial Information

Part I. Financial Information

Financial Statements

Item 1. Financial Statements Owens & Minor, Inc. and Subsidiaries Condensed Consolidated Statements of Operations (unaudited) Three Months Ended Nine Months Ended September 30, September 30, (in thousands, except per share data) 2025 2024 2025 2024 Net revenue $ 697,264 $ 686,846 $ 2,053,065 $ 1,985,089 Operating costs and expenses: Cost of net revenue 375,067 355,075 1,087,024 1,037,700 Selling, general and administrative expenses 265,838 272,322 796,061 812,453 Transaction breakage fee — — 80,000 — Acquisition-related charges and intangible amortization 29,229 14,855 66,603 42,905 Exit and realignment charges, net 660 13,515 16,826 37,062 Total operating costs and expenses 670,794 655,767 2,046,514 1,930,120 Operating income 26,470 31,079 6,551 54,969 Interest expense, net 29,029 28,953 79,252 79,949 Transaction financing fees, net — — 18,288 — Other expense, net 1,076 1,168 2,993 2,869 (Loss) income from continuing operations before income taxes ( 3,635 ) 958 ( 93,982 ) ( 27,849 ) Income tax provision (benefit) 1,972 ( 303 ) ( 743 ) ( 8,974 ) (Loss) income from continuing operations, net of tax ( 5,607 ) 1,261 ( 93,239 ) ( 18,875 ) Loss from discontinued operations, net of tax ( 144,669 ) ( 14,031 ) ( 951,077 ) ( 47,695 ) Net loss $ ( 150,276 ) $ ( 12,770 ) $ ( 1,044,316 ) $ ( 66,570 ) Basic loss per common share: (Loss) income from continuing operations, net of tax $ ( 0.07 ) $ 0.02 $ ( 1.21 ) $ ( 0.25 ) Loss from discontinued operations, net of tax ( 1.87 ) ( 0.19 ) ( 12.34 ) ( 0.62 ) Net loss $ ( 1.94 ) $ ( 0.17 ) $ ( 13.55 ) $ ( 0.87 ) Diluted loss per common share: (Loss) income from continuing operations, net of tax $ ( 0.07 ) $ 0.02 $ ( 1.21 ) $ ( 0.25 ) Loss from discontinued operations, net of tax ( 1.87 ) ( 0.18 ) ( 12.34 ) ( 0.62

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing